Clinical Research Directory

Inclusion Criteria: 1. Age ≥18 years and ≤75 years. 2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC). 3. No prior systemic anti-tumor therapy. 4. ECOG performance status 0-2 and life expectancy ≥12 weeks. 5. At least one measurable lesion per RECIST version 1.1. 6. No brainstem metastasis and no significant neurological symptoms from brain metastases. 7. All participants must undergo routine contrast-enhanced CT of the chest and upper abdomen, as well as brain MRI, before enrollment. Whole-body PET-CT plus brain MRI is preferred. For participants with limited financial resources who also have significant obstructive pneumonia or atelectasis, an additional chest MRI is recommended. 8. No malignant pleural effusion or pericardial effusion. 9. All participants must provide written informed consent. Exclusion Criteria: 1. Presence of interstitial pneumonia or infectious fever prior to treatment. 2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment). 3. Prior history of thoracic radiotherapy or thoracic surgery. 4. Presence of Grade ≥3 hematologic toxicity or hepatic/renal impairment. 5. Hypersensitivity to adebrelimab. 6. Significant respiratory symptoms that preclude tolerance to radiotherapy. 7. Active hepatitis B or hepatitis C infection with ongoing antiviral therapy. Subjects with a documented history of HBV infection who have achieved undetectable HBV levels after prior active treatment at the time of enrollment may be included. 8. Presence of pleural effusion or pericardial effusion.